IDXX’s 6.6% Decline in a Day Brings Valuations Into Focus – Is EW a Better Deal?
Edwards Lifesciences (EW) offers superior revenue growth across key periods, better profitability, and relatively lower valuation vs IDEXX Laboratories (IDXX), suggesting you may be better off investing in EW
- EW’s quarterly revenue growth was 6.2%, vs. IDXX’s 3.6%.
- In addition, its Last 12 Months revenue growth came in at 7.9%, ahead of IDXX’s 5.6%.
- EW’s 3-year average margin is stronger: 29.9% vs. IDXX’s 28.7%.
IDXX develops and distributes veterinary diagnostic products, instruments, consumables, and test kits for companion animals, livestock, poultry, dairy, and water quality testing markets. EW provides structural heart disease products, critical care, and surgical monitoring technologies, including aortic surgical valves, distributed via direct sales and independent distributors.
Valuation & Performance Overview
| IDXX | EW | Preferred | |
|---|---|---|---|
| Valuation | |||
| P/EBIT Ratio | 37.9 | 30.3 | EW |
| Revenue Growth | |||
| Last Quarter | 3.6% | 6.2% | EW |
| Last 12 Months | 5.6% | 7.9% | EW |
| Last 3 Year Average | 6.3% | 1.8% | IDXX |
| Operating Margins | |||
| Last 12 Months | 29.1% | 27.7% | IDXX |
| Last 3 Year Average | 28.7% | 29.9% | EW |
| Momentum | |||
| Last 3 Year Return | 33.9% | -21.1% | IDXX |
Note: For “Last 3 Year Return” metric, preferred stock is one with higher returns unless the returns are too high (>300%) which creates risk of sell off.
See more revenue details: IDXX Revenue Comparison | EW Revenue Comparison
See more margin details: IDXX Operating Income Comparison | EW Operating Income Comparison
But do these numbers tell the full story? Read Buy or Sell EW Stock to see if Edwards Lifesciences’s edge holds up under the hood or if IDEXX Laboratories still has cards to play (see Buy or Sell IDXX Stock).
- How To Earn 8.2% Yield While Waiting to Buy WYNN 30% Cheaper
- What Could Light a Fire Under Costco Wholesale Stock
- The Hidden Dangers Facing Amazon.com Stock
- Cash Rich, Low Price – Ardent Health Stock to Break Out?
- Momentum Meets Value: Centrus Energy Stock Could Be A Good Buy
- High Margins, 34% Discount: Buy Visa Stock Now
That is one way to look at stocks. Trefis High Quality Portfolio evaluates much more, and is designed to reduce stock-specific risk while giving upside exposure
Historical Market Performance
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Total [1] | Avg | Best | |
|---|---|---|---|---|---|---|---|---|---|
| Returns | |||||||||
| IDXX Return | 91% | 32% | -38% | 36% | -26% | 29% | 116% | <=== | |
| EW Return | 17% | 42% | -42% | 2% | -3% | 7% | 3% | ||
| S&P 500 Return | 16% | 27% | -19% | 24% | 23% | 8% | 98% | ||
| Monthly Win Rates [3] | |||||||||
| IDXX Win Rate | 75% | 58% | 42% | 50% | 42% | 83% | 58% | ||
| EW Win Rate | 50% | 75% | 33% | 58% | 75% | 50% | 57% | ||
| S&P 500 Win Rate | 58% | 75% | 42% | 67% | 75% | 50% | 61% | <=== | |
| Max Drawdowns [4] | |||||||||
| IDXX Max Drawdown | -30% | -7% | -51% | -4% | -27% | -13% | -22% | ||
| EW Max Drawdown | -33% | -14% | -47% | -17% | -22% | -9% | -24% | ||
| S&P 500 Max Drawdown | -31% | -1% | -25% | -1% | -2% | -15% | -12% | <=== | |
[1] Cumulative total returns since the beginning of 2020
[2] 2025 data is for the year till date (YTD)
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
No matter how good the numbers, stock investment is never a smooth ride. There is a risk you must factor in. Read EW Dip Buyer Analyses and IDXX Dip Buyer Analyses to see how these stocks have fallen and recovered in the past.